{"id":745220,"date":"2015-04-19T07:30:00","date_gmt":"2015-04-19T07:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/"},"modified":"2025-11-07T01:25:16","modified_gmt":"2025-11-07T06:25:16","slug":"keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/","title":{"rendered":"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy&#8230;"},"content":{"rendered":"<p class=\"bwalignc\">       &#8230;in a Phase 3 Study of Patients with Advanced Melanoma     <\/p>\n<p class=\"bwalignc\">       Data from KEYNOTE-006 Study Presented at AACR Annual Meeting and        Published in the New England Journal of Medicine     <\/p>\n<p class=\"bwalignc\">       Merck Plans to Submit sBLA for First-Line Indication in Advanced        Melanoma in Mid-2015     <\/p>\n<\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced results from the randomized, pivotal Phase 3 study,<br \/>\n      KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the<br \/>\n      study, KEYTRUDA<sup>\u00ae<\/sup> (pembrolizumab) was statistically superior<br \/>\n      to ipilimumab for progression-free survival (PFS), overall survival<br \/>\n      (OS), and overall response rate (ORR). On March 24, 2015, Merck<br \/>\n      announced that KEYNOTE-006 would be stopped early based on these data (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.mercknewsroom.com%2Fnews-release%2Foncology-newsroom%2Fmercks-pivotal-keynote-006-study-first-line-treatment-advanced-melano&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=link&amp;index=1&amp;md5=3e453115e3169a0b88603fe5df7335d3\" rel=\"nofollow\">link<\/a>).<br \/>\n      The results will be presented today at the American Association for<br \/>\n      Cancer Research (AACR) Annual Meeting by Dr. Antoni Ribas of Jonsson<br \/>\n      Comprehensive Cancer Center, University of California, Los Angeles<br \/>\n      (abstract # CT101), included in the AACR press program, and were also<br \/>\n      published today in the <i>New England Journal of Medicine.<\/i>\n    <\/p>\n<p>\n      \u201cImproving survival is the ultimate objective in treating patients with<br \/>\n      cancer. In this important study in advanced melanoma, KEYTRUDA was<br \/>\n      statistically superior to ipilimumab for progression-free survival and<br \/>\n      overall survival, and also demonstrated a lower frequency of severe<br \/>\n      adverse events.\u201d said Dr. Caroline Robert, head of dermatology at<br \/>\n      Gustave Roussy, Villejuif and Paris-Sud University Cancer Campus, Grand<br \/>\n      Paris and lead author of the <i>New England Journal of Medicine<\/i><br \/>\n      publication.\n    <\/p>\n<p>\n      In mid-2015, Merck plans to submit a supplemental Biologics License<br \/>\n      Application (sBLA) for KEYTRUDA based on KEYNOTE-006 for the first-line<br \/>\n      treatment of advanced melanoma. Merck recently submitted data from<br \/>\n      KEYNOTE-002 in ipilimumab-refractory advanced melanoma as part of a<br \/>\n      supplemental application. KEYTRUDA was the first anti-PD-1 therapy<br \/>\n      approved in the United States and is currently indicated in the United<br \/>\n      States for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. Please see below for complete<br \/>\n      indication and selected safety information for KEYTRUDA.\n    <\/p>\n<p>\n      \u201cOur goal with the KEYTRUDA development program is to help improve<br \/>\n      long-term disease control and survival for people suffering from a wide<br \/>\n      range of cancers,\u201d said Dr. Roger Perlmutter, president, Merck Research<br \/>\n      Laboratories. \u201cThe KEYNOTE-006 study compared two immunotherapies that<br \/>\n      target distinct immune checkpoint pathways, PD-1 and CTLA-4. In this<br \/>\n      study, our anti-PD-1 antibody, KEYTRUDA, improved overall survival by<br \/>\n      more than 30 percent compared to ipilimumab, an anti-CTLA-4 antibody, in<br \/>\n      the treatment of advanced melanoma. We look forward to filing these data<br \/>\n      with the FDA and health authorities around the world.\u201d\n    <\/p>\n<p>\n      <b>KEYNOTE-006 Results in the Front-Line Treatment of Advanced Melanoma<\/b>\n    <\/p>\n<p>\n      KEYNOTE-006 is a global, open-label, randomized, pivotal, Phase 3 study<br \/>\n      (ClinicalTrials.gov, NCT01866319) of 834 patients from 16 countries with<br \/>\n      unresectable stage III or IV advanced melanoma with no more than one<br \/>\n      prior systemic therapy. Patients received KEYTRUDA 10 mg\/kg every two<br \/>\n      weeks (n=279), KEYTRUDA 10 mg\/kg every three weeks (n=277), or four<br \/>\n      cycles of ipilimumab 3 mg\/kg every three weeks (n=278). The primary<br \/>\n      endpoints were PFS and OS; secondary endpoints were ORR, duration of<br \/>\n      response, and safety. Tumor response was assessed at week 12, then every<br \/>\n      six weeks thereafter by independent central review per RECIST 1.1. This<br \/>\n      first presentation of data from KEYNOTE-006 is based on interim analyses<br \/>\n      conducted for PFS with a data cut-off of September 3, 2014 (median<br \/>\n      follow-up, 7.9 months) and for OS with a data cut off of March 3, 2015<br \/>\n      (median follow-up, 13.8 months).\n    <\/p>\n<p>\n      <i><b>Data Showed KEYTRUDA was Statistically Superior to Ipilimumab for<br \/>\n      PFS, OS and ORR<\/b><\/i>\n    <\/p>\n<p>\n      The median PFS for KEYTRUDA was 5.5 months (2-week group) and 4.1 months<br \/>\n      (3-week group) compared to 2.8 months for ipilimumab (HR 0.58, <i>P&lt;<\/i>0.00001<br \/>\n      for the KEYTRUDA groups vs. ipilimumab, 95% CI, 0.46-0.72 for 2-week<br \/>\n      group and 0.47-0.72 for 3-week group, respectively). The estimated<br \/>\n      6-month PFS rates for the KEYTRUDA and ipilimumab arms were 47.3<br \/>\n      percent, 46.4 percent and 26.5 percent, respectively. One-year OS for<br \/>\n      KEYTRUDA was 74.1 percent (2-week group) and 68.4 percent (3-week group)<br \/>\n      compared to 58.2 percent for ipilimumab (HR 0.63 [95% CI, 0.47-0.83, <i>P=<\/i>0.00052]<br \/>\n      for the 2-week group and HR 0.69 [95% CI, 0.52-0.90, <i>P=<\/i>0.00358]<br \/>\n      for the 3-week group). At the time of analysis, median overall survival<br \/>\n      was not reached in any treatment group.\n    <\/p>\n<p>\n      ORR for KEYTRUDA was 33.7 percent (2-week group) and 32.9 percent<br \/>\n      (3-week group) compared to 11.9 percent for ipilimumab (<i>P=<\/i>0.00013<br \/>\n      for 2-week group; <i>P=<\/i>0.00002 for 3-week group); complete response<br \/>\n      rates were 5.0 percent, 6.1 percent, and 1.4 percent, respectively.<br \/>\n      Responses were ongoing in 89.4 percent (2-week group) and 96.7 percent<br \/>\n      (3-week group) of KEYTRUDA-treated patients and in 87.9 percent of<br \/>\n      ipilimumab-treated patients. Median duration of response was not reached<br \/>\n      for KEYTRUDA 3-week group (42+ to 246+) and ipilimumab (33+ to 239+).\n    <\/p>\n<p>\n      The efficacy and safety profiles were similar between the two KEYTRUDA<br \/>\n      schedules evaluated in the study. Two previous studies, KEYNOTE-001 and<br \/>\n      KEYNOTE-002, demonstrated that the efficacy and safety were similar<br \/>\n      among the KEYTRUDA doses and schedules evaluated; 10 mg\/kg every two<br \/>\n      weeks, 10 mg\/kg every three weeks, and 2 mg\/kg every three weeks (the<br \/>\n      currently approved dose in the U.S.).\n    <\/p>\n<p>\n      <i><b>Safety Findings from KEYNOTE-006<\/b><\/i>\n    <\/p>\n<p>\n      The safety profile of KEYTRUDA in this study was generally consistent<br \/>\n      with the safety described in the prescribing information. The most<br \/>\n      common treatment-related adverse events of any grade occurring in the<br \/>\n      KEYTRUDA groups were fatigue, diarrhea, rash, and pruritus. For<br \/>\n      ipilimumab, the most frequent treatment-related adverse events were<br \/>\n      pruritus, diarrhea, fatigue, and rash. Grade 3 to 4 treatment-related<br \/>\n      adverse events occurred in 13.3 percent (2-week group) and 10.1 percent<br \/>\n      (3-week group) of patients treated with KEYTRUDA and in 19.9 percent for<br \/>\n      ipilimumab. Discontinuation due to treatment-related adverse events was<br \/>\n      less frequent with KEYTRUDA (2-week group and 3-week group) than with<br \/>\n      ipilimumab (4.0%, 6.9%, and 9.4%, respectively). One death in the<br \/>\n      ipilimumab group was attributed to study treatment.\n    <\/p>\n<p>\n      Treatment-related adverse events of an autoimmune or immune-related<br \/>\n      nature most frequently observed with KEYTRUDA (2-week group and 3-week<br \/>\n      group) were hypothyroidism (10.1% and 8.7%) and hyperthyroidism (6.5%<br \/>\n      and 3.2%). With ipilimumab, colitis occurred in 8.2 percent of patients.<br \/>\n      Grade 3 to 4 inflammatory or immune-mediated treatment events reported<br \/>\n      in more than 1 percent of KEYTRUDA-treated patients (2-week group and<br \/>\n      3-week group) were colitis (1.4% and 2.5%) and hepatitis (1.1% and<br \/>\n      1.8%), and in ipilimumab-treated patients were colitis (7.0%) and<br \/>\n      hypophysitis (1.6%).\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 85 clinical trials \u2013 across more than 30<br \/>\n      tumor types and over 14,000 patients \u2013 both as a monotherapy and in<br \/>\n      combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>About Melanoma<\/b>\n    <\/p>\n<p>\n      Melanoma, the most serious form of skin cancer, is characterized by the<br \/>\n      uncontrolled growth of pigment-producing cells. The incidence of<br \/>\n      melanoma has been increasing over the past four decades \u2013 approximately<br \/>\n      232,130 new cases were diagnosed worldwide in 2012. In the U.S.,<br \/>\n      melanoma is one of the most common types of cancer diagnosed and is<br \/>\n      responsible for the vast majority of skin cancer deaths. In 2014, an<br \/>\n      estimated 76,100 people were expected to be diagnosed and an estimated<br \/>\n      9,710 people were expected to die of the disease in the U.S. alone. The<br \/>\n      five-year survival rates for advanced or metastatic melanoma (Stage IV)<br \/>\n      are estimated to be 15 to 20 percent.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=2&amp;md5=af18c42ec5882f9bc7bef7bb28b969c5\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today\u2019s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=3&amp;md5=431510950e712c5d812a8e08c59c1524\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=5f8e329561f6f9b813b763fa02414521\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=Facebook&amp;index=5&amp;md5=463219fd4fe175665a28c2d27d9ca431\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=YouTube&amp;index=6&amp;md5=ae9ac06f40bbd3a7c7f069b343f50035\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=4dad6cfa300d8c7412ce7ab0f84f495b\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=3b0b272aa98dbad5a307110c911c6d65\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51082741&amp;newsitemid=20150419005027&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=7c92596cf298f65fef79b0a2ee30adf5\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150419005027r3&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Investors:<br \/>Joseph        Romanelli, 908-740-1986<br \/>or<br \/>Justin Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA \u00ae (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, 2015, Merck announced that KEYNOTE-006 would be stopped early based on these data ( link ). The results will be presented today at the American Association for Cancer Research (AACR) Annual Meeting by Dr. Antoni Ribas of Jonsson Comprehensive Cancer Center, University of California, Los Angeles (abstract # CT101), included in the AACR press program, and were also published today in the New England Journal of Medicine. \u201cImproving survival is the ultimate objective in treating patients with cancer. In this important study in advanced melanoma, KEYTRUDA was statistically superior to ipilimumab for<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745220","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA \u00ae (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, 2015, Merck announced that KEYNOTE-006 would be stopped early based on these data ( link ). The results will be presented today at the American Association for Cancer Research (AACR) Annual Meeting by Dr. Antoni Ribas of Jonsson Comprehensive Cancer Center, University of California, Los Angeles (abstract # CT101), included in the AACR press program, and were also published today in the New England Journal of Medicine. \u201cImproving survival is the ultimate objective in treating patients with cancer. In this important study in advanced melanoma, KEYTRUDA was statistically superior to ipilimumab for\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\\\/\",\"name\":\"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-19T07:30:00+00:00\",\"dateModified\":\"2025-11-07T06:25:16+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy&#8230;\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/","og_locale":"en_US","og_type":"article","og_title":"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com","og_description":"Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the randomized, pivotal Phase 3 study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, KEYTRUDA \u00ae (pembrolizumab) was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR). On March 24, 2015, Merck announced that KEYNOTE-006 would be stopped early based on these data ( link ). The results will be presented today at the American Association for Cancer Research (AACR) Annual Meeting by Dr. Antoni Ribas of Jonsson Comprehensive Cancer Center, University of California, Los Angeles (abstract # CT101), included in the AACR press program, and were also published today in the New England Journal of Medicine. \u201cImproving survival is the ultimate objective in treating patients with cancer. In this important study in advanced melanoma, KEYTRUDA was statistically superior to ipilimumab for","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:16+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/","name":"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy... - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-19T07:30:00+00:00","dateModified":"2025-11-07T06:25:16+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/keytruda-pembrolizumab-mercks-anti-pd-1-therapy-demonstrates-superior-survival-progression-free-survival-and-overall-response-rate-compared-to-ipilimumab-an-anti-ctla-4-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s Anti-PD-1 Therapy, Demonstrates Superior Survival, Progression Free Survival and Overall Response Rate Compared to Ipilimumab an Anti-CTLA-4 Therapy&#8230;"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"0792dcb7-7c0c-4efa-b002-881dda86b405","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/KEYTRUDA-pembrolizumab-Mercks-Anti-PD-1-Therapy-Demonstrates-Superior-Survival-Progression-Free-Survival-and-Overall-Response-Rate-Co-0XL8V.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745220","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745220\/revisions"}],"predecessor-version":[{"id":3674657,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745220\/revisions\/3674657"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745220"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745220"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}